Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering regulatory elements for conditionally-replicative adeno-viruses.

Yosef S Haviv1, David T Curiel

  • 1Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294-2172, USA. yosef.haviv@ccc.uab.edu

Current Gene Therapy
|July 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.

Nature communications·2026
Same author

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same author

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Molecular therapy. Oncology·2026
Same author

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Nature communications·2026
Same author

An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.

Cell reports. Medicine·2026
Same author

Response to "Considerations for integrating SGLT2 inhibitors into systemic lupus erythematosus management: Opportunities and challenges" by Chen et al.

Seminars in arthritis and rheumatism·2025

Replication-selective viruses, particularly adenoviruses (Ads), offer potent cancer therapy by amplifying and targeting tumors. Type III conditionally replicative adenoviruses (CRAds) show improved tumor selectivity and oncolysis, advancing cancer treatment potential.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Adenovirus engineering

Background:

  • Virus-mediated oncolysis is a promising cancer therapy approach.
  • Replication-selective viruses offer advantages over non-replicating vectors, including in-situ amplification and novel cell killing mechanisms.
  • Tumor selectivity is crucial for replication-selective viruses to ensure safety and efficacy.

Purpose of the Study:

  • To review the development and potential of oncolytic adenoviruses (Ads) for cancer therapy.
  • To discuss the strategies for engineering tumor-specific replication in adenoviruses.
  • To highlight the advantages of Type III conditionally replicative adenoviruses (CRAds).

Main Methods:

  • Review of existing literature on oncolytic adenoviruses and CRAd development.

Related Experiment Videos

  • Classification of CRAds into Type I, Type II, and Type III based on genomic modification strategies.
  • Analysis of the tumor-targeting and oncolytic capabilities of different CRAd types.

    • Main Results:

    • Adenoviruses possess attributes suitable for oncolytic therapy, including genomic modifiability and high oncolytic capacity.
    • Type I and Type II CRAds achieve tumor-specific replication through gene deletion/mutation or tissue-specific regulatory elements, respectively.
    • Type III CRAds, combining Type I and II strategies, demonstrate enhanced tumor selectivity and oncolysis, offering improved therapeutic indices.

    Conclusions:

    • Conditionally replicative adenoviruses (CRAds) represent a significant advancement in oncolytic virotherapy.
    • Type III CRAds show superior tumor selectivity and oncolytic potential compared to earlier types.
    • Further research into the biological aspects of CRAds is needed to fully realize their potential as first-line cancer therapeutics.